Hybio Pharmaceutical

Hybio Pharmaceutical Co., Ltd. (Abbreviation: Hybio Pharmaceutical, Stock Code: 300199) is a national high-tech enterprise specializing in the research, production, and sales of peptide drugs. It has established the National-Local Joint Engineering Laboratory for Peptide Drugs, the National Public Experimental Center for Peptide Innovative Drugs, the National Pilot Technology Platform for Peptide Drug Preparation, and the National High-Tech Industrialization Demonstration Project Base for Peptide Drugs. With peptide drugs as its foundation and core, the company integrates other categories such as advanced chemical drugs, focusing on the research and development of chronic disease medications for diabetes, cardiovascular diseases, multiple sclerosis, and more. The company actively explores the integration of pharmaceuticals, medical devices, and mobile internet, expanding its product lines to cover testing, treatment, rehabilitation, and daily care for patients with chronic diseases, achieving its strategic development goal of becoming an expert in chronic disease management.